Appendix 4E and Annual Report

Aug 19, 2026 at 3:24 AM EDT · Issued by Percheron Therapeutics Limited via ASX

Filed with ASX · Aug 19, 2026 at 3:24 AM EDT

On 6ix: 6ix.com/news/appendix-4e-and-annual-report-233

ASX Announcement Percheron Therapeutics Limited ABN 41 095 060 745 ASX: PER | FSE: AWY | US OTC: ATHJY PERCHERON THERAPEUTICS LIMITED ANNUAL REPORT Melbourne, Australia – 19 August 2026: Percheron Therapeutics Limited (ASX: PER) (‘the Company’), advises that...

View Attachment

6ix hasn’t read this filing yet.

Percheron Therapeutics Limited on 6ix

Earlier from Percheron Therapeutics

Appendix 4G and Corporate Governance StatementAug 18
Application for quotation of securities - PERAug 14
Notice of date of AGM and other relevant datesAug 11
Percheron Therapeutics Announces CEO SuccessionAug 9
Quarterly Activities Report and Appendix 4CJul 30

Later from Percheron Therapeutics

Vanderbilt Health to conduct clinical trial of HMBD-002Aug 27
Trading HaltAug 27
Percheron receives $0.70m R&D Tax Incentive RebateAug 30
Notification of cessation of securities - PERAug 31
Change of Director's Interest NoticeAug 31

All Percheron Therapeutics news releases

Follow Percheron Therapeutics into a list and get an email when it puts out news.

Follow Percheron Therapeutics